Your DNA For Sale: The 23andMe SPAC Bankruptcy
On March 24, 2025, 23andMe filed for Chapter 11 bankruptcy. The company that once promised to revolutionize personalized medicine — and was valued at $6.0Bat its peak — was dead. But this wasn't just another SPAC failure. This one came with a uniquely dystopian twist: 15 million customers' DNA records were now assets of a bankrupt estate, potentially headed for auction.
Your genetic code — the most personal data imaginable — was about to be sold to the highest bidder.
The SPAC Deal
23andMe went public through a merger with VG Acquisition Corp, a SPAC backed by Sir Richard Branson (Virgin Group). The deal closed in June 2021, capitalizing on the consumer genetics boom and retail investor enthusiasm for anything associated with Branson's brand.
Peak price: $17.65. The pitch was compelling: 23andMe had a massive consumer database, a recognizable brand, and a nascent drug development arm that could leverage genetic data to discover new therapeutics. The total addressable market in personalized medicine was "trillions."
But the business model had fundamental problems that the SPAC hype obscured.
A One-Time Purchase Problem
23andMe's core product — a DNA testing kit — is a one-time purchase. Once you've had your DNA sequenced, there's no reason to do it again. The company tried to build recurring revenue through subscription health reports, but conversion rates were abysmal. Most customers spit in a tube once, checked their ancestry results, and never came back.
The drug development pipeline, which justified the $6 billion valuation, was years from generating revenue and required massive R&D investment. The consumer business couldn't fund the drug business, and the SPAC trust proceeds were burning faster than new products could be developed.
The Data Breach That Changed Everything
In October 2023, 23andMe disclosed that hackers had accessed genetic data of approximately 6.9 million users through credential stuffing attacks. The stolen data included ancestry information, genetic health predispositions, and family connections. It was one of the most sensitive data breaches in history.
The breach destroyed whatever remaining consumer trust the company had. New customer acquisitions plummeted. Existing users began requesting data deletion. The stock, already in freefall, accelerated its decline.
The Bankruptcy and the DNA Question
23andMe filed for bankruptcy on March 24, 2025 — 45months after going public via SPAC. The company's stock went to zero. But the most disturbing implication of the bankruptcy wasn't financial — it was biological.
In bankruptcy, all of a company's assets are potentially for sale. For 23andMe, those assets include the genetic data of approximately 15 million customers. DNA data — including health predispositions, ancestry, and familial connections — could theoretically be sold to pharmaceutical companies, insurance companies, data brokers, or anyone else willing to bid.
The dystopian reality:15 million people trusted 23andMe with the most intimate data possible — their DNA. That data is now an asset on a bankruptcy balance sheet. California's Genetic Information Privacy Act provides some protections, but the legal landscape for genetic data in bankruptcy is largely untested.
Richard Branson's SPAC Legacy
23andMe was the second Branson-backed SPAC to go bankrupt, after Virgin Orbit (filed April 2023). Combined peak market cap destroyed across Branson's SPAC ventures: $9.7B.
Branson himself remains a billionaire. His personal exposure to SPAC losses was negligible relative to his net worth. The retail investors who bought VG Acquisition Corp units because of Branson's involvement lost everything.
What This Means for SPAC Investors
The 23andMe bankruptcy is the most consequential SPAC failure in terms of societal impact. Other SPAC bankruptcies destroyed money. This one may compromise the genetic privacy of millions of people.
It's also a perfect illustration of why SPACs are dangerous for companies that need patient, long-term capital. 23andMe's drug development strategy might have worked with a decade of private funding and careful, incremental development. The SPAC model demanded growth on a public market timeline, with quarterly earnings pressure and a stock price that reflected expectations, not reality.
The SPAC didn't just fail the investors. It may have failed 15 million people who never bought a single share.
Bankruptcy filing data from United States Bankruptcy Court records. Data breach details from 23andMe SEC filings and FTC reports. Genetic privacy analysis based on GIPA and federal legal frameworks.